Monopar Therapeutics MNPR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's additional paid-in capital?
- Monopar Therapeutics (MNPR) reported additional paid-in capital of $228.69M in Q1 2026.
- How has Monopar Therapeutics's additional paid-in capital changed year-over-year?
- Monopar Therapeutics's additional paid-in capital increased by 73.2% year-over-year, from $132.03M to $228.69M.
- What is the long-term trend for Monopar Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Monopar Therapeutics's additional paid-in capital has grown at a 36.5% compound annual growth rate (CAGR), from $47.87M to $227.2M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.